--- a
+++ b/clusters/9knumclustersv2/clust_1453.txt
@@ -0,0 +1,150 @@
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =<  x ULN (=<  x ULN for patients with documented liver metastases)
+Aspartate aminotransferase (AST) ? .  ULN without liver metastases; must be ?   ULN with liver metastases
+Alanine aminotransferase (ALT) ? .  ULN without liver metastases; must be ?   ULN with liver metastases
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? .  ULN or ?   ULN for patients with liver metastases
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . x ULN (or =< . x ULN if liver metastases are present)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ?  x ULN; if liver metastases are present, then ?  x ULN is allowed.
+Serum transaminases (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) =< . x ULN in the absence of liver metastases and =<  x ULN in case of liver metastases
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x ULN (=<  x ULN in patients with liver metastases)
+Alanine aminotransferase or aspartate aminotransferase < . x the ULN or <  x the ULN if secondary to liver metastasis
+Within  (except as noted) days of planned treatment initiation: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< . x institutional ULN OR =<  x ULN for patients with known liver metastases
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < . x ULN or <  x ULN if liver metastases
+PHASE II INCLUSION CRITERIA: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < . x ULN or <  x ULN if liver metastases
+Aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase =< . x ULN, or =<  x ULN in subjects with liver metastases within  days of treatment initiation and must be independent of hematopoietic growth factor support
+In the absence of liver metastases, alanine aminotransferase (AST) and aspartate aminotransferase (ALT) should be below .  ULN. If the participant has liver metastases, ALT and AST should be below .  ULN.
+alanine aminotransferase /aspartate aminotransferase (ALT/AST) ?. x ULN without, and ?  x ULN with hepatic metastases
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =<  x ULN or =<  x ULN for patients with liver metastases within  weeks of pre-registration
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x ULN or =<  x ULN if liver metastases
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . ULN or =<  x ULN if liver mets are present
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ?.  institutional ULN OR ?  institutional ULN for participants with liver metastases
+Alanine aminotransferase (AST) and aspartate aminotransferase (ALT) =< . x ULN (or =<  x ULN if liver metastases are present)
+Patients are eligible with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) up to  x ULN; (up to  x ULN if liver metastases present)
+Alanine aminotransferase ?  x ULN or ?  x ULN if liver metastasis is present.
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< . x ULN for patients without liver metastasis, =<  times for patients with liver metastases
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =<  X ULN (or <  x ULN with liver metastases)
+Aspartate aminotransferase (AST) =< . x ULN or =<  x ULN if judged by the investigator to be related to liver metastases
+Alanine aminotransferase and aspartate aminotransferase =< . x ULN, (=< . x ULN with documented liver metastases) within  days prior to first dose of protocol-indicated treatment.
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?x the ULN (?x the ULN for subjects with liver metastases)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? . x ULN, unless liver metastases are present, then values must be ?  x ULN)
+Within  days prior to registration: Aspartate aminotransferase (AST) =< . x ULN (or =<  x ULN if liver metastases)
+Within  days prior to registration: Alanine aminotransferase (ALT) =< . x ULN (or =<  x ULN if liver metastases)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x institutional ULN OR =<  x ULN for subjects with liver metastases
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x ULN, unless liver metastases are present, then values must be =<  x ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ?  x institutional ULN (?  x ULN in the presence of liver metastases)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ?  x ULN (or ? . x ULN if hepatic metastases are present)
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< . x ULN OR =<  x ULN for subjects with liver metastases
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =<  x ULN, unless associated with hepatobiliary metastases, in that case =<  x ULN
+Within  days prior to enrollment: Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< . X ULN OR =<  X ULN for subjects with liver metastases
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . x ULN (results within  days before study drug administration), =<  x ULN for patients with liver metastases
+Performed within  days of treatment initiation: Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< . X ULN OR =<  X ULN for subjects with liver metastases
+alanine aminotransferase (ALT, SGPT) and aspartate aminotransferase (AST, SGOT) ? . x ULN (?  x ULN if liver metastases are present);
+Determined within  weeks of treatment initiation: Aspartate aminotransferase (AST) =< . x ULN OR =<  x ULN for subjects with liver metastases
+Determined within  weeks of treatment initiation: Alanine aminotransferase (ALT) =< . x ULN OR =<  x ULN for subjects with liver metastases
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >  x ULN (>  x ULN if liver metastases are present)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . x ULN unless liver metastases are present, in which case it must be =<  x ULN.
+Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ? . x ULN or ? x ULN if known liver metastases
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x ULN if no demonstrable liver metastases or =<  x ULN in the presence of liver metastases
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =<  x ULN (ALT and AST =<  x ULN is acceptable if liver metastases are present)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =<  x ULN or =<  x ULN if liver metastases are present
+In absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) should be below .  ULN. If the patient has liver metastases, ALT and AST should be <   ULN.
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT):\r\n* > . x ULN\r\n* >  x ULN, if liver metastasis present
+Aspartate aminotransaminase (AST) and alanine aminotransferase (ALT) =< . x ULN OR =< . x ULN if liver metastases present
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =< . x ULN; if liver metastases are present, then AST and ALT =<  x ULN
+Transaminases (aspartate aminotransferase-AST and alanine aminotransferase ALT) =< . x ULN (=<  x ULN if liver metastases are present)
+Aspartate aminotransferase and/or alanine aminotransferase =<  x ULN (=<  x ULN if liver metastases are present) within  days prior to CD
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . x ULN (or =< . x ULN if hepatic metastases are present)
+Aspartate aminotransferase (AST) =< . x ULN; =<  x ULN if liver metastases are present
+Alanine aminotransferase (ALT) =< . x ULN; =<  x ULN if liver metastases are present
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =<  x ULN (or =< . x ULN if hepatic metastases are present)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x ULN or =<  x ULN for subjects with liver metastases
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . x ULN or =<  x ULN if liver metastases are present
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . x ULN or =<  x ULN if liver metastases are present
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =<  x ULN (in the case of liver metastases, =<  x ULN)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =<  x ULN for patients without liver metastasis, =<  x ULN for liver metastases
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =<   ULN or <   ULN in the setting of liver metastases
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x ULN (=<  x ULN in patients with liver metastases)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? . x ULN without liver metastases (or ?  x ULN if liver metastases are present)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? . x ULN (?  x ULN for subjects with liver metastases)
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) < . x institutional ULN or =<  x the institution ULN in the presence of known liver metastases
+Aspartate aminotransferase (AST) =< . x ULN; note: if the patient has liver metastases present, then =<  x ULN
+Alanine aminotransferase (ALT) =< . x ULN; note: if the patient has liver metastases present, then =<  x ULN
+Hepatic: bilirubin <. X ULN; alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < . X ULN. Patients with known liver metastases or liver neoplasms: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < . X ULN
+Within  days prior to randomization: Aspartate aminotransferase (AST) and alanine aminotransaminase (ALT) must be =< . x ULN for the lab or =<  x ULN for patients with liver metastases.
+Within  days of first dose of study drug: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =<  x ULN; if liver metastases, then =<  x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x ULN or =<  x upper limits of normal (ULN) if liver metastases are present =<  days prior to registration
+Aspartate aminotransferase (AST) ?  x ULN OR ?  x ULN (if liver metastases present)
+Alanine aminotransferase (ALT) ?  x ULN OR ?  x ULN (if liver metastases present)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . x ULN unless liver metastases are present, in which case it must be =< x ULN.
+Liver function tests performed within  weeks prior to starting study therapy must have alanine aminotransferase and aspartate aminotransferase =< . x ULN (or =<  x ULN if liver metastases are present)
+Aspartate aminotransferase (AST), alanine aminotransferase (ALT) or alkaline phosphatase < . x ULN OR =<  x ULN for subjects with liver metastases
+To be performed within  days prior to day  of protocol therapy: Aspartate aminotransferase (AST) =< . x ULN if no liver metastases or =<  x ULN if liver metastases
+To be performed within  days prior to day  of protocol therapy: Alanine aminotransferase (ALT) =< . x ULN if no liver metastases or =<  x ULN if liver metastases
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =<  x ULN (=<  x ULN for patients with documented liver metastases)
+Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) =< . x upper limit of normal (ULN) but =< . x ULN in case of liver metastases; in the presence of liver metastases the liver isoenzyme fraction must be measured and liver isoenzyme fraction (absolute value) must be =<  x ULN
+In absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x ULN; if the patient has liver metastases, ALT and AST =< . x institutional ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . times ULN in subjects without liver metastases or =< . times ULN in subjects with liver metastases
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =<  x ULN (=<  x ULN for patients with documented liver metastases)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x ULN (=<  x ULN in patients with liver metastases)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< . x upper limit of normal (ULN) for patients with liver metastases and =< . x ULN for patients without liver metastases
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . times ULN (or . x ULN in the setting of liver metastases)
+Aspartate aminotransferase (AST) =< . x ULN, or =<  x ULN if liver metastases are present
+Alanine aminotransferase (ALT) =< . x ULN, or =<  x ULN if liver metastases are present
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< . ULN if without liver metastases
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< to . times the ULN if no liver metastases; for patients with known liver metastases, AST and ALT must be =< to  times the ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< . x ULN for patients without liver metastases and =<  x ULN for patients with liver metastases
+aspartate aminotransferase, alanine aminotransferase ? . X ULN, or ? . X ULN (if liver metastasis present)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< . x ULN (=<  x ULN in the presence of liver metastases)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . x ULN OR =< . x ULN if liver metastases present (within  days prior to day  of protocol therapy)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x ULN, unless liver metastases are present, then values must be =<  x ULN)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< . X ULN; <  X ULN if known hepatic metastases =<  days prior to randomization
+Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) up to . x ULN if no liver metastases or ALT or AST up to  x ULN if liver metastases present
+Within  h of initiating study treatment: Aspartate aminotransferase (AST) =< . x ULN OR <  x ULN for liver metastases (mets)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =<  x ULN, unless associated with hepatobiliary metastases, in that case =<  x ULN
+Aspartate aminotransferase (AST) =< . X ULN (=< . X ULN if liver metastases are present)
+Alanine aminotransferase (ALT) =< . X ULN (=< . X ULN if liver metastases are present)
+Alanine aminotransferase (ALT), and aspartate aminotransferase (AST) =< . x ULN (for patients with liver metastases, =<  x ULN)
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< . X ULN OR =<  X ULN for subjects with liver metastases
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< . x ULN for patients without liver metastasis, =<  times for liver metastases
+The aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must not be more than . x ULN within  hours prior to enrollment, or greater than . X ULN if in the Investigators judgment it is related to liver metastases; AST and ALT may be up to  x ULN within  hours prior to enrollment in participants with hepatic metastases
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >. x upper limit of normal (ULN) if no demonstrable liver metastases or > x ULN in the presence of liver metastases
+Aspartate aminotransferase (AST) =< . x ULN, or =<  x ULN if liver metastases are present
+Alanine aminotransferase (ALT) =< . x ULN, or =<  x ULN if liver metastases are present
+No liver metastases: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . x ULN; liver metastases: AST and ALT =<  x ULN
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x ULN (=<  x ULN in patients with liver metastases)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . x ULN (=<  x ULN if liver metastases are present)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < . x ULN (or <  x ULN if known liver metastases)
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . x ULN in the absence of liver metastases; AST and ALT =<  x ULN in the presence of liver metastases
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x ULN (=<  x ULN in patients with liver metastases)
+Alanine aminotransferase (ALT) =< . x ULN or =<  x ULN if liver metastases persist
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . x ULN for institution or =<  x ULN for institution if clearly attributable to liver metastases
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT): ~ . x ULN for subjects without liver metastasis ~  times for liver metastases
+For subjects without liver metastases: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x ULN
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< . x ULN (=<  x ULN if liver metastases are present)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)  =< . x ULN or =< . x ULN for subjects with liver metastases
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . x ULN (=< . ULN in the presence of liver metastases)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT): =< . x ULN for subjects without liver metastasis; =<  times for liver metastases
+Alanine aminotransferase (AST) or aspartate aminotransferase (ALT) > . x ULN (or < . x ULN if liver metastases are present)
+Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) <  x ULN (<  x ULN for patients with documented liver metastases)
+Serum transaminases (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) ? . x ULN in the absence of liver metastases or =<  ULN in case of liver metastases)
+Aspartate aminotransferase ?  ULN for the reference lab (?  ULN for subjects with known hepatic metastases)
+Alanine aminotransferase ?  ULN for the reference lab (?  ULN for subjects with known hepatic metastases)
+Aspartate aminotransferase (AST) and alkaline phosphatase =< . x ULN (CTCAE v. grade ; AST and alanine aminotransferase [ALT] =<  x ULN [or =< . x ULN if hepatic metastases are present])
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ?  x ULN (or <  x ULN in subjects with liver metastases or hepatocellular carcinoma).
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . x ULN or =<  x ULN if liver metastases are present
+Alanine aminotransferase (ALT) =< . x ULN; if liver metastases are present, =<  x ULN
+Hepatic: Direct bilirubin ?. X ULN; alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ? . X ULN. For patients with known liver metastases or liver neoplasms, then ALT or AST ? . X ULN is allowed
+Aspartate aminotransferase (AST)/Alanine transferase (ALT) (SGOT/SGPT) < . x ULN for the reference laboratory or <  x ULN in the presence of liver metastases
+Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) ?. X ULN (? x ULN in patients with liver metastases)
+Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< . x ULN (with or without liver metastases)
+Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ? . x ULN or ? x ULN if known liver metastases
+Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) <  x ULN or <  x ULN if known liver metastases
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? .  ULN unless liver metastases are present, in which case they must be ?   ULN
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? .  ULN unless liver metastases are present, in which case they must be ?  ULN
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) less than or equal to . x ULN unless liver metastasis is present then up to  X ULN permitted
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< . x ULN or =<  x ULN if liver metastases are present
+Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) <  X ULN in case of liver metastases
+Alanine aminotransferase (ALT) =< . x ULN or =<  x ULN if liver metastases persist
+Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <  x ULN (<  x ULN if liver metastases are present)
+Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< . x ULN for patients without liver metastasis, =<  times for liver metastases
+Aspartate aminotransferase (AST) =< . x upper limit of normal range (ULN); for subjects with known liver metastases =<  x ULN, and alanine aminotransferase (ALT) =< . x ULN; for subjects with known liver metastases =<  x ULN
+Alanine aminotransferase (ALT) =< . x ULN OR <  x ULN for subjects with liver metastases, obtained within  days prior to C-AMT PET scan